Anti-cancer nuclear hormone receptor-targeting compounds

A compound of Formula III, IV, V or VI, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof:

• wherein:
• each R1, R2, R3 and R4 is independently -L-(B)m, hydrogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-10 cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(═O)R5, —C(═O)OR5, —C(═O)NR5R6, —S(═O)1-2R5, —S(═O)1-2NR5R6, —NR5S(═O)1-2R6 or —C═NOR5, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl of R1, R2, R3 and R4 are independently optionally substituted with one or more R10 as valency permits;
• m is 1, 2, or 3;
• each L is independently a covalent bond or a linking moiety;
• each B is independently a nuclear receptor-targeting epitope;
• each R10 is independently halo, cyano, nitro, —OR7, —SR7, —SF5, —NR7R8, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-10 cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(═O)R7, —C(═O)OR7, —OC(═O)OR7, —OC(═O)R7, —C(═O)NR7R8, —OC(═O)NR7R8, —NR7C(═O)NR7R8, —S(═O)1-2R7, —S(═O)1-2NR7R8, —NR7S(═O)1-2R8, —NR7S(═O)1-2NR7R8, —NR7C(═O)R8, —NR7C(═O)OR8 or —C═NOR7, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl of R10 are independently optionally substituted with one or more halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino as valency permits;
• and
• each R5 and R6 is independently hydrogen, deuterium, C1-12 alkyl or C3-12 cycloalkyl, optionally substituted with oxo, halo, hydroxyl or amino as valency permits;
• or R5 and R6 are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino;
• each R7 and R8 is independently hydrogen, deuterium or C1-12 alkyl optionally substituted with oxo, halo, hydroxyl or amino as valency permits;
• or R7 and R8 are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino;
• and
• R9 is hydrogen or R2;
• provided that at least one R1, R2, R3 and R4 is -L-(B)m.

A compound of Formula IIIB, IVA, VB or VIA, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof:

• wherein:
• R2 is -L-(B)m;
• m is 1, 2, or 3;
• L is a covalent bond or a linking moiety;
• and
• each B is independently a nuclear receptor-targeting epitope.